Pulmatrix is committed to developing breakthrough therapies for the treatment of pulmonary disease.  Pulmatrix has the ability to develop single and combination therapies that will provide advances in current standard of care and novel drug formulations that will improve patient outcomes, compliance, and convenience.  Pulmatrix is particularly focused on improving the lives of patients and chronic respiratory diseases including:

- Cystic Fibrosis (CF) »

- Chronic Obstructive Pulmonary Disease (COPD) »

- Idiopathic Pulmonary Fibrosis (IPF) »

iSPERSE offers the ability to uniquely enable novel therapeutics in these disease areas in a convenient patient friendly configuration:

High drug load anti-infective formulations: iSPERSE enables the high drug loads (>10 mg) necessary for pulmonary activity of anti-infective drugs

Novel dose limited small molecules: iSPERSE flow rate independent performance enables delivery of small molecules at doses not possible with lactose blend formulations

Inhaled macromolecules: iSPERSE enables delivery of active proteins and nucleic acids for local and systemic action

Novel dual and triple combinations: iSPERSE enables consistent delivery of dual and triple combinations, including LABA-LAMA-ICS

© 2018 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   applications   publications   news   careers   contact   site design